Qiagen and DiaSorin partner on tuberculosis testing

Qiagen has announced a new partnership with DiaSorin that will allow the companies to offer new automated tuberculosis detection capabilities for their customers.

The collaboration will see Qiagen's QuantiFERON-TB diagnostic test added to the menu of DiaSorin's Liaison family of fully automated analysers, allowing customers of both companies to process QuantiFERON-TB results on Liaison platforms.

This will allow Liaison users to utilise the gold-standard Qiagen test to safeguard at-risk patients by screening for latent tuberculosis infection through a fully automated, flexible workflow. More than 7,000 Liaison systems have been placed worldwide, primarily in hospital laboratories.

DiaSorin and Qiagen will launch a CE Mark-approved version of the new QuantiFERON readout components for use on Liaison XL systems in the third quarter of 2018, with US availability is planned for 2019 and a Chinese launch scheduled for 2020.

Peer Schatz, chief executive officer of Qiagen, said: "We are pleased to partner with DiaSorin and create a compelling fully automated solution for our QuantiFERON-TB test, and plans for this to be followed by more QuantiFERON-based tests in the future."

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.